Date: 2017-06-15
Type of information: Collaboration agreement
Compound: in vitro and ex vivo testing for hepatotoxicity and metabolism
Company: CitoxLab (France) KaLy-Cell (France)
Therapeutic area: Technology - Services
Type agreement: collaboration
Action mechanism:
Disease:
Details:
- • On June 15, 2017 , CiToxLAB, a leading CRO in the field of non-clinical research, announced its partnership with KaLy-Cell, a company specialized in the evaluation of hepatic toxicity and in vitro and ex vivo metabolism tests. This partnership will allow both companies to meet the growing demand from clients in the pharmaceutical, biotech and chemical industries for predictive tests to evaluate hepatotoxicity and to perform metabolism studies during product development.
- KaLy-Cell was founded in 2003 by Professor Lysiane Richert. It offers in vitro and ex vivo studies to evaluate hepatotoxicity and detect potential drug-drug interactions. The company is involved in several European projects (such as EuroTransBio and IMI), bringing together hospitals, pharmaceutical companies and renowned university laboratories. It also contributes to the validation of regulatory tests in collaboration with EURL-ECVAM, the European reference laboratory for alternatives to animal testing.
- With this partnership, in vitro and ex vivo testing (using hepatocytes and liver microsomes) will allow companies to evaluate hepatotoxicity and the potential effects linked to hepatic metabolism disorders; at early stages and during preclinical and clinical phases of development. The use of cultured multi-species hepatocytes will allow companies
- – to evaluate in vitro hepatic clearance (metabolite stability),
- – to identify the structure of resulting metabolites (Qtrap Orbitrap- Q exactive™),
- – to identify potential drug-drug interactions (cytochrome P450 and transporters),
- – to determine endocrine disrupting potential (i.e. thyroid and steroidal hormones),
- – to investigate the mechanisms using transcriptomics (Affymetrix™ technology or RT-PCR).
Financial terms:
Latest news:
Is general: Yes
